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Abstract
Background: RNA interference (RNAi) is a powerful platform utilized to target transcription of specific genes and
downregulate the protein product. To achieve effective silencing, RNAi is usually applied to cells or tissue with a
transfection reagent to enhance entry into cells. A commonly used control is the same transfection reagent plus a
“noncoding RNAi”. However, this does not control for the genomic response to the transfection reagent alone or in
combination with the noncoding RNAi. These control effects while not directly targeting the gene in question may
influence expression of other genes that in turn alter expression of the target. The current study was prompted by
our work focused on prevention of vascular bypass graft failure and our experience with gene silencing in human
aortic smooth muscle cells (HAoSMCs) where we suspected that off target effects through this mechanism might
be substantial. We have used Next Generation Sequencing (NGS) technology and bioinformatics analysis to
examine the genomic response of HAoSMCs to the transfection reagent alone (polyethyleneimine (PEI)) or in
combination with commercially obtained control small interfering RNA (siRNAs) (Dharmacon and Invitrogen).
Results: Compared to untreated cells, global gene expression of HAoSMcs after transfection either with PEI or in
combination with control siRNAs displayed significant alterations in gene transcriptome after 24 h. HAoSMCs
transfected by PEI alone revealed alterations of 213 genes mainly involved in inflammatory and immune responses.
HAoSMCs transfected by PEI complexed with siRNA from either Dharmacon or Invitrogen showed substantial gene
variation of 113 and 85 genes respectively. Transfection of cells with only PEI or with PEI and control siRNAs
resulted in identification of 20 set of overlapping altered genes. Further, systems biology analysis revealed key
master regulators in cells transfected with control siRNAs including the cytokine, Interleukin (IL)-1, transcription
factor GATA Binding Protein (GATA)-4 and the methylation enzyme, Enhancer of zeste homolog 2 (EZH-2) a
cytokine with an apical role in initiating the inflammatory response.
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Conclusions: Significant off-target effects in HAoSMCs transfected with PEI alone or in combination with control
siRNAs may lead to misleading conclusions concerning the effectiveness of a targeted siRNA strategy. The lack of
structural information about transfection reagents and “non coding” siRNA is a hindrance in the development of
siRNA based therapeutics.
Keywords: RNAi, Transfection reagent, PEI, Control siRNA
Background
RNAi is an emerging technology using a natural mech-
anism to inhibit gene expression via the degradation of
target mRNAs through siRNA. We have been exploring
RNAi for the purpose of modifying the vascular re-
sponse to injury especially during graft implantation,
employing endothelial cells and vascular smooth muscle
cells, under various conditions and technology for
siRNA delivery [1–4]. Although these studies have dis-
played promise of RNAi therapy as an alternative means
to treat vascular diseases, there is so far no study dis-
cussing how transfection reagent alone and in combin-
ation with non-targeting (control) siRNAs affect gene
expression level.
Our group is interested in developing siRNA based
therapies to treat vascular bypass grafts, both vein and
prosthetic, to prevent vascular graft failure. Injury to the
graft and the host artery during graft implantation is the
most important trigger for the downstream graft failure.
Vascular smooth muscle cells play a major role in the
failure process and thus are often targeted for thera-
peutic intervention. Thus in the present study the cells
chosen were HAoSMCs [1–4].
When determining the effectiveness of siRNA silen-
cing of a target gene, the standard control has been a
comparison with control siRNA. In our laboratory we
have used a series of controls. For example, if using a
transfection reagent, our controls would be: 1. Saline
alone. 2. Transfection reagent alone. 3. Transfection re-
agent plus control siRNA. We have noticed differences
between these controls with regard to expression of the
target gene, raising the question of the control effects on
total genomic expression. For example, if the transfec-
tion reagent alters target gene expression and that is
different from the transfection reagent plus the control
siRNA, which is the better control? Can we count on
the control siRNA to have no effect on target gene
expression? Should saline or balanced salt solution be
the appropriate control as it is least likely to affect target
gene transcription? In this study, experiments were
designed to determine the global effects on gene
transcription of saline, a transfection reagent, and the
transfection reagent plus control siRNA using RNA
sequencing. Since our goal is to treat vascular bypass
grafts with siRNA, we chose a transfection reagent PEI,
as this is frequently used for in vivo applicability.
Control siRNAs were obtained from Invitrogen and
Dharmacon.
Results
Unsupervised clustering suggests that untreated (NT) and
HAoSMCs treated with P, PI and PD are transcriptionally
different
HAoSMCs were either treated with PEI alone (P), Invitro-
gen control siRNA complexed with PEI (PI) or Dharmacon
control siRNA complexed with PEI (PD) for 24 h.
HAoSMCs that were left untreated (NT) served as the
experimental control. After treatment, cells were subjected
to RNA isolation as described above. After preprocessing
and normalization of RNA sequencing data we performed
unsupervised analysis using PCA to determine relationship
between different treatment groups as well as samples
within each group. The unsupervised analysis demon-
strated that samples are separated on the basis of transfec-
tion that is NT versus P, PI and PD along primary
component (PC) 1 (Fig. 1). The samples from PEI alone
group depicted maximum transcriptional differences as
compared to control NT, PI and PD groups along primary
component (PC) 2. Biological replicates from most of the
groups clustered together indicating similar transcriptome
profile.
Inflammation and apoptosis related genes are
upregulated/activated due to PEI transfection
PEI (P), which comes in two forms; linear and branched
polymer, has been extensively used as a non-viral
cationic carrier to deliver drugs or genes into the cells
via proton sponge effects [5]. The supervised compari-
son of NT samples with P only samples identified 213
significantly differentially expressed genes with false
discovery rate <5 % and at least 2-fold change. Out of 213
differentially expressed genes, 115 and 98 were significantly
downregulated and upregulated respectively (Fig. 2a and
Additional file 1: Table S2). Treatment with P upregulated
multiple genes linked to cell-mediated immune response
and inflammatory response including Prostaglandin-
Endoperoxide Synthase (PTGS) 2, Nicotinamide phosphor-
ibosyltransferase (NAMPT), most prominently several
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chemokines and chemokine receptors genes such as
Chemokine (C-X-C motif) Ligand (CXCL)-2, CXCL-11,
CXCL-8, IL-1A, IL-11, Chemokine (C-C motif) Ligand
(CCL)-5 and Colony Stimulating Factor (CSF)-2 (Fig. 2a).
To understand the underlying biological mechanism of
alterations induced due to PEI treatment, we performed
gene-ontology (GO) categories and canonical pathways
analysis. The GO analysis of differentially expressed genes
identified significantly affected categories (P value <0.01)
that include cytokine activity, inflammatory response,
chemokine activity and immune response (Fig. 2b).
Furthermore, pathways analysis on the list of differentially
expressed genes identified significant pathways (multiple
test corrected P value <0.01) that include, Granulocyte
Adhesion and Diapedesis, peroxisome proliferator-
activated receptor (PPAR) signaling, IL-10 signaling, and
IL-6 signaling (Fig. 2c). These pathways that are triggered
by immune systems in response to PEI transfection, play a
critical role in multiple diseases including cancer,
immunological and neurodegenerative diseases. The acti-
vation of immune and inflammatory pathways 24 h after
in vitro transfection with PEI at the vendor recom-
mended N/P ratio in HAoSMCs suggests toxicity
associated with PEI.
Transcriptional alterations due to control siRNA
compared to PEI alone
To understand the non-specific transcriptional alter-
ations induced by control siRNA when combined with
PEI, we performed global RNA sequencing on sam-
ples transfected with control unlabeled siRNA from
Invitrogen or Dharmacon combined with PEI. The
transfection of samples with control unlabeled siRNA
from Invitrogen or Dharmacon compared to PEI
alone significantly altered (FDR <5 % and FC > ± 2)
132 and 85 genes respectively (Fig. 3a and Additional
file 1: Table S3A, S3B). A significant number (64) of
genes were commonly altered by unlabeled siRNA
Fig. 1 Principle Component Analysis (PCA) of HAoSMCs that were treated as follows: No Treatment (NT), PEI alone (P), PEI combined with control
siRNA from Invitrogen (PI) and PEI combined with control siRNA from Dharmacon siRNA (PD). PCA analysis of three replicates in each treatment
group suggests that NT and HAoSMCs treated with P, PI and PD form different clusters indicating that these treatment groups are
transcriptionally different from each other
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from Invitrogen or Dharmacon (Fig. 3b and Additional
file 1: Table S4) suggesting similar mechanisms that may
affect transcriptional profile of the cells. To understand
the biological mechanism underlying the alterations in-
duced by control siRNA transfection, we performed func-
tional and pathways enrichment analysis on the genes that
were commonly altered by both Invitrogen and Dharma-
con control siRNA. The functions uniting commonly
differentially expressed genes were dominated by func-
tions involved in cell proliferation and growth and im-
mune/inflammatory response (Fig. 3c). Further pathways
analysis on commonly affected genes depicted signifi-
cant enrichment in inflammatory response pathways
including Granulocyte/Agranulocyte Adhesion and Diape-
desis. These pathways are the primary line of host
defense against infection by bacterial pathogens and
Fig. 2 Transcriptional and biological characterization of alteration in HAoSMC induced by PEI. (a) Heatmap of genes that are significantly differentially
expressed due to treatment with PEI alone (P) compared to No Treatment (NT). In the heatmap, rows depict differentially expressed genes and
columns depict three replicates each of NT and P treated HAoSMC. The relative expression level of genes is shown using a pseudocolor scale from −3
to +3. Colors indicate standardized values (green represents down regulation and red represents up regulation). (b) Functional categories enrichment
analysis of all significantly differentially expressed genes, and (c) Pathways enrichment analysis of all significantly differentially expressed genes
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are rapidly recruited to sites of bacterial invasion sug-
gesting that control siRNAs are probably recognized
as foreign entities [6].
Control siRNA and PEI lead to immune systems and
inflammation related transcriptional changes
Compared to NT, transfection of cells with either PI or
PD resulted in significant transcriptional changes (Fig. 4a).
The transfection of cells with PI resulted in dysregulation
of 66 genes (Additional file 1: Table S5A), mostly
dominated by genes linked to inflammation related path-
ways including “Agranulocyte/Granulocyte Adhesion and
Diapedesis”, “Farnesoid X Receptor/ Retinoid X Receptor
(FXR/RXR) Activation”, “Acute Phase Response Signal-
ing”, “Dendritic Cell Maturation”, “IL-6 Signaling”, “p38
Mitogen-Activated Protein Kinase (MAPK) Signaling”,
and “PPAR Signaling” (Fig. 4b). Similarly, transfection of
cells with PD resulted in dysregulation of 78 genes
(Additional file 1: Table S5B), which are dominated by
genes linked to inflammation related pathways com-
parable to PI (Fig. 4b). Thus, transfection with both
Dharmacon and Invitrogen non-targeting control
siRNAs resulted in inflammation response similar to
host defense response against infection of bacteria’s or
Fig. 3 Transcriptional characterization of alteration induced in HAoSMC by transfection with PEI combined with control siRNA from Invitrogen (PI) or
Dharmacon (PD). (a) Heat map of significantly differentially expressed genes due to transfection with PI or PD, (b) Functional categories significantly
altered due to transfection with PI, (c) Functional categories that depict pattern of alteration (Raw P value < .01) due to transfection with PD. No
functional category was found significant after multiple test correction, and (d) Venn diagram depicting genes common between HAoSMC treated
with PI and PD
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viruses described above. The analysis identified a core
set of 20 overlapping genes that are significantly
altered due to transfection of cells with P, PI or PD
(Table 1). This core set of overlapping genes is domi-
nated by genes linked to immune/inflammatory and
cell proliferation including Kinesin Family Member
(KIF)-1A, STAT-4, CCL-8, Superoxide Dismutase
(SOD)-2, IL-36B, CSF-2, and IL3-6RN (Fig. 4c). These
genes have also been linked to vascular dysregulation
and the associations are listed in Table 2.
Systems biology oriented analysis of control siRNA
transcriptional changes to identify key master
regulators
To gain further insight into the impact of control siRNA
transfection of cells, we performed systems biology
oriented analysis on the transcripts that are differentially
expressed after transfection with PI or PD. The regulatory
analysis was performed using Ingenuity Pathway Analysis
(IPA) 8.0 (www.ingenuity.com). The regulatory analysis of
the transcripts that were differentially expressed after
transfection with PI depicted activation of IL-1 response
(Fig. 5a). IL-1 is a key inflammatory cytokine and its over-
expression leads to inflammatory responses by initiating
Nuclear Factor Kappa Beta (NFKB) cascade, edema, and
the growth of leukocytes [7]. In addition to IL1, there was
also a strong activation of immune response as illustrated
by the upregulation of multiple proinflammatory chemo-
kines and cytokines as well as NFKB cascade (e.g. IL1A,
IL1B, NFKB complex, IL-1, IL-15, IL-17A, IL-18, Toll-
Like Receptor (TLR)-4) and their upstream and down-
stream target molecules (Fig. 5b). Similar analysis of PD
transfected cells revealed involvement of cell proliferation
and growth related molecules such as GATA-4 and EZH-
2. These results suggest that control siRNA, irrespective
of the brand (Dharmacon or Invitrogen) can lead to
Fig. 4 Transcriptional characterization of alteration induced in HAoSMC by PEI alone (P) or PEI combined with control siRNA from Invitrogen (PI)
or Dharmacon (PD). (a) Venn Diagram depicting overlap among the genes that are differentially expressed in HAoSMC due to P alone, PI or PD
as compared to no treatment (NT), (b) Functions significantly altered due to transfection with PI and PD, (c) Pathways significantly altered due to
transfection with PI and PD, and (d) Heatmap of 20 common significantly differentially expressed genes due to transfection with P, PI or PD
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Table 1 List of commonly significantly differentially expressed genes due to transfection of PEI alone (P), and PEI with Invitrogen (PI)
and Dharmacon (PD) control siRNA respectively
Genes P vs. NT PI vs. NT PD vs. NT
Log FC P value FDR log FC P value FDR Log FC PV value FDR
KRT5 −9.00108542 1.82E-08 9.11E-07 −9.00108542 1.12E-08 1.85E-06 −9.00108542 4.00E-09 5.77E-07
DSC2 −5.547567862 9.33E-06 0.000210938 −7.514505361 3.54E-07 3.79E-05 −5.843576549 2.01E-06 0.00010804
CASP14 −4.866920217 1.36E-06 3.98E-05 −6.718742357 9.08E-09 1.56E-06 −3.84210716 2.16E-05 0.000762738
PKP1 −4.065832231 4.03E-05 0.000734415 −5.837618386 4.72E-07 4.98E-05 −4.812633855 2.41E-06 0.000126389
SFN −3.866190605 1.96E-05 0.000390234 −2.706646929 0.000813618 0.022294014 −5.116141429 1.68E-07 1.47E-05
XIST −2.6415241 0.000447384 0.005355807 −4.189237025 9.64E-07 9.24E-05 −2.564333239 0.000399303 0.007636661
KIF1A −2.37198378 0.001162629 0.011613329 −6.165808144 1.86E-09 3.89E-07 −2.639316704 0.000279027 0.005863775
PABPC1L −1.469888511 5.36E-08 2.38E-06 −1.136168153 1.40E-05 0.000867902 −1.006563861 7.85E-05 0.002217316
MMRN2 −1.148174676 2.51E-05 0.000484772 −1.125962103 2.61E-05 0.00144306 −1.140277865 1.12E-05 0.00044101
STAT4 1.030820203 0.00090642 0.009359621 1.164708993 0.000135637 0.005691294 1.401188438 2.28E-06 0.000120413
ELN 1.327728145 5.88E-23 1.68E-20 1.389401412 3.20E-25 1.34E-21 1.303860319 1.21E-22 1.52E-19
CCL8 1.434021582 2.81E-11 2.43E-09 1.621652693 1.26E-14 8.32E-12 1.716686958 7.40E-17 3.37E-14
SOD2 1.461039459 3.51E-39 2.20E-36 1.007297504 7.52E-20 1.18E-16 1.329823799 5.71E-33 1.79E-29
CNTNAP2 1.550048726 6.82E-17 1.17E-14 1.167033839 4.31E-10 1.13E-07 1.302670483 1.60E-12 4.10E-10
C8orf4 1.657269124 1.89E-46 2.16E-43 1.214785377 1.07E-25 6.74E-22 1.229534359 1.34E-26 3.37E-23
NR3C2 1.839357043 6.15E-12 6.08E-10 1.505931617 3.47E-08 4.93E-06 1.89042933 2.94E-13 7.86E-11
IL36B 2.065054755 1.81E-13 2.09E-11 1.371901177 1.91E-06 0.000158997 1.623123119 7.63E-09 1.01E-06
CSF2 2.157136236 2.41E-36 1.38E-33 1.04449791 5.99E-10 1.46E-07 1.692407468 1.62E-23 2.77E-20
AMH 2.487063814 2.12E-08 1.05E-06 1.631133689 0.00045514 0.014311243 2.135611981 1.50E-06 8.61E-05
IL36RN 4.508694239 2.15E-34 1.12E-31 3.347303687 2.41E-18 2.33E-15 3.737917275 1.76E-23 2.77E-20
Table 2 Effects of the altered genes after transfection of cells with PEI and control siRNAs on vascular system in the literature
Genes Effects on vascular system References
KRT5 Overexpression enhanced vascular proliferation leading to cell hyperplasia in urinary bladder [31]
DSC2 Mutations may predict arrhythmic events and sudden cardiac death [32]
CASP14 Deletion may be the cause of vascular neurodegenerative disorder [33]
PKP1 Overexpression in head and neck tumor tissues [34]
SFN Inhibited intimal hyperplasia in rat carotid injury model [35]
MMRN2 Overexpression impaired tumor growth through VEGF pathway interference [36]
STAT4 Upregulated during intimal hyperplasia [9]
ELN Aberrations caused aortic aneurysm [37]
CCL8 Reduced macrophage accumulation in the vascular wall and blood pressure in hypertension. [8]
SOD2 Protected against oxidative stress and endothelial dysfunction in carotid artery [38]
C8orf4 Used as an endothelial inflammatory marker [10]
NR3C2 Under expression may cause angiogenesis in colorectal carcinomas [39] [39]
Contributed to vascular remodeling and target organ damage [40] [40]
CSF2 Stimulated arteriogenesis in pig peripheral artery disease model [41]
AMH Upregulation associated with varicose vein disease [42]
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activation of the immune and growth pathways at the
transcriptional level.
Validation of changes in key genes using qRT-PCR
To confirm our findings from the RNASeq study using
qRT-PCR we validated a few key genes that were differ-
entially regulated and are known to be involved in
vascular dysfunction [8–11]. Our results confirm that as
compared to NT, HAoSMC treated with P, PI and PD
show an upregulation of CCL8, STAT4, IL-1a and IL-1b
gene expression (Fig. 6). Consistent with our RNASeq
data, most significant effects were observed with
HoASMC treatment with P and PD. With significant
changes in global gene expression, housekeeping genes
may also show differential expression, making them un-
reliable and thereby discrediting the qRT-PCR analysis.
PEI is known to affect the gene expression of commonly
used housekeeping gene Glyceraldehyde-3-Phosphate
Dehydrogenase (GAPDH) [12], hence in this study we
used another commonly used housekeeping gene, B2M.
Expression of B2M gene was not different between the
different treatment groups suggesting that B2M could be
used reliably as a housekeeping gene.
Discussion and Conclusions
We have examined in detail the transcriptome re-
sponse to a commonly used transfection reagent, PEI
alone or in combination with one of two commonly
used control siRNAs (Invitrogen or Dharmacon). Our
results demonstrate a broad and significant change in
the transcriptome in response to the transcription
reagent and a further change as a result of addition
of the control siRNA.
Our data demonstrate that the transcription reagent
PEI induces an extensive transcriptome response in cul-
tured AOSMC. The affected genes include several genes
that might be seen as targets in an RNAi therapeutic
strategy such as for the treatment of vascular diseases,
cancer or modifying the inflammatory response. For
example, PTGS2 or Cylcooxygenase (COX)-2 that are
altered in our present study are associated with athero-
sclerosis and have been shown to be upregulated by the
prostacyclin-mimetic, iloprost in human vascular SMC
[13]. Similarly, another altered gene in the study,
NAMPT, is also linked to atherosclerosis and its inhib-
ition has attenuated atherosclerotic plaque formation
through CXCL-1 mediated activities on neutrophils [14].
The PEI effect is additionally altered when the control
siRNA is combined with the PEI. Pathways analysis of
commonly affected genes showed significant enrichment
in inflammatory response pathways including Granulo-
cyte/Agranulocyte Adhesion and Diapedesis. The genes
involved in these pathways are the primary line of host
defense against bacterial infection and are rapidly
recruited to sites of bacterial invasion [6]. System biol-
ogy analysis further demonstrated overexpression of
inflammatory ctyokines such as IL-1, CCL-8, GATA-4
and EZH-2. IL1 and CCL8 are prominent inflammatory
cytokines implicated in multiple inflammatory diseases
such as atherosclerosis, rheumatoid arthritis (RA) and
Alzheimer’s diseases [15, 16]. GATA 4 is involved in
Fig. 5 Interactive network of top regulatory molecules significantly altered in HAoSMC by treatment with PEI combined with control siRNA from
Invitrogen (PI) or Dharmacon (PD). a PI, and (b) PD
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transcription and cell maturation and has been shown to
be associated with multiple cancers and cardiovascular
diseases [17–21]. EZH-2 activation results in increase in
histone methylation causing inhibition of multiple tumor
suppressor genes resulting in cancer progression. It is in-
teresting to note that our results are contradictory to the
findings obtained in the study of off-target effects in hu-
man fibroblast cells after being transfected with control
siRNAs obtained commercially [22]. While present study
showed enhancement in inflammatory responses, their
study demonstrated inhibition of innate immune system
through the reduction of NFκB signaling after the cells
were transfected with control siRNAs [22]. However, it
could be possible that this is a cell-specific effect. We
have previously reported differential susceptibility of
endothelial and smooth muscle cells to different trans-
fection reagents [23, 24].
In the end, the transcriptome of a commonly used
control for RNAi experiments is no longer representa-
tive of the transcriptome of untreated cells. Whether this
response to PEI will hold for other transfection reagents
remains to be seen. However until proven otherwise it is
prudent to assume that is the case and not limit controls
in RNAi cell culture studies to the transfection reagent
Fig. 6 Validation of differentially regulated genes using qRT-PCR in HAoSMC that were either left untreated (NT) or treated with PEI alone (P), PEI
combined with control siRNA from Invitrogen (PI), or Dharmacon (PD). Gene expression of (a) CCL8, (b) STAT4, (c) IL-1α, (d) IL-1β, and (e) raw Ct
value of B2M. (*P < 0.05, **P < 0.01 and ***P < 0.001)
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combined with a control siRNA. The present study justi-
fies the use of two additional controls: untreated cells,
and transfection reagent alone. These controls will
determine if the target gene expression is altered and
whether it is a consequence of the transfection re-
agent alone or transfection reagent combined with a
control siRNA.
Our data show that gene silencing studies using PEI in
conjunction with either of the two popular control siR-
NAs must be regarded as relative to a very altered tran-
scriptome. This places limits on the predictive value for
clinical application of many gene-silencing experiments.
For example, an experiment might be designed to see if
siRNA can effectively diminish expression of IL-1, a key
inflammatory cytokine involved in numerous diseases.
Demonstration of effectiveness might then lead to con-
sideration of therapeutic use of IL-1 siRNA to control
the disease. However, the consequences of the transfec-
tion reagent and the control siRNA may increase expres-
sion of IL-1 to the point where, even with relative
silencing, the expression of IL-1 is actually greater than
in the resting cell state. It would then be a mistake to
assume that the same RNAi strategy would be effective
as a therapeutic in the control of the disease using IL-1
as a target. In fact, it might be harmful because the net
effect would be an increase in expression of the
undesired gene. Our data show the multiple biologic
systems that respond to the transfection reagent, espe-
cially inflammatory and immune related pathways. This
is understandable based on the cell membrane injury
associated with PEI. Less clear is the source of the
additional transcriptome response precipitated by the
control siRNA.
With regard to therapeutic strategies, global expression
consequences of a transfection reagent and non-coding
siRNA might also be harmful by increasing expression of
off target genes that have undesired effects. Or, the strat-
egy might decrease expression of genes that have desired
effects. Of note here, is that we have examined one time
point, 24 h. However it is possible that dysregulated off
target genes seen at 24 h might subsequently have down-
stream effects on the chosen target at a later time-point.
These are important considerations in designing transla-
tional experiments using in vivo models. Before predicting
the ultimate outcome of silencing a high profile target, it
is necessary to follow the complete flare of the transcrip-
tome response to the transfection reagent plus siRNA.
This is extremely important for our work focused on the
use on siRNA-based therapy for the prevention of graft
failure. Vascular graft failure is a multi-factorial and
sequential phenomenon with complex components
including smooth muscle and endothelial cells. The work
presented here is an attempt to understand the basic re-
sponse of the smooth muscle cells to PEI and the different
control siRNAs. Eventually, we will be conducting similar
study in other cell types including endothelial cells before
embarking on the use of PEI in an in vivo study. More im-
portantly, irrespective of the disease model, any siRNA-
based therapy will be subjected to a similar scrutiny before
its use in an in vivo system.
Based on our study, it can be argued that the global
transcriptome response of any RNAi based strategy
should be determined before commencing clinical tri-
als. Off target effects must be assumed and should be
clearly defined to minimize the risk of doing more
harm than good.
Methods
Cell culture
HAoSMCs (Lonza, Walkersville, MD) were cultured in
basal medium Clonetics smooth muscle cell (SMC)
medium (SmGM-2, CAT# CC-3181, Lonza) enriched
with the supplied SMC growth additives (Insulin, CAT#
CC-4021D; hFGF-B, CAT# CC-4068D; GA-1000, CAT#
CC-4081D, FBS, CAT# CC-4102D, hEGF, CAT# CC-
4230D, Lonza). The cells were maintained in a humidi-
fied incubator at 37 °C with 5 % CO2. Cells from pas-
sages 6–9 were used in the experiments.
siRNA transfection
HAoSMCs were seeded at a density of 3x105 cells/well in a
6-well flat-bottom plate. The total volume of each well was
3 ml. Twenty four hours later, cells were transfected with
transfection reagent alone or with 50 nM of either control
siRNA from Invitrogen (CAT# 4390843, Invitrogen,
Carlsbad, CA) or control siRNA from Dharmacon
(CAT#ID D-001206-13-20, Dharmacon, Lafayette, CO) ac-
cording to manufacturer’s protocol. JetPEI™ (Polyplus, NY)
with nitrogen in PEI to phosphate in siRNA (N/P) ratio of
10 was used as the transfection reagent. This ratio has been
optimized in our recently published work [3]. Cells in
culture medium without any treatment were used as
experimental control. Master mix was created for each
individual condition in order to eliminate pipetting errors
and to increase consistency between each well. Each treat-
ment condition was performed in triplicate.
RNA isolation
After 24 h of transfection, HAoSMCs were lysed with
Buffer RLT (Qiagen, Limburg, Netherlands). Total RNA
was extracted and purified using RNeasy Mini Kit
(Qiagen, Limburg, Netherlands) with an optional step:
addition of DNase I mix to remove any genomic DNA
contamination and to enhance the quality of RNA. RNA
concentrations for each sample were obtained using
NanoDrop 2000 spectrophotometer (Thermo Scientific,
Wilmington, DE).
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Transcriptome profiling using RNA quantification
sequencing
Transcriptomes derived from HAoSMCs that were un-
treated (NT), treated with PEI only (P), PEI with control
siRNA from Invitrogen (PI) or PEI with control siRNA
from Dharmacon (PD) were subjected to next-generation
sequencing (NGS) to generate deep coverage RNASeq
data. For each treatment group, sequencing was per-
formed on three biological replicates. Sequencing libraries
were generated from the double-stranded cDNA using the
Illumina TruSeq kit according to the manufacturer’s
protocol. Library quality control was checked using the
Agilent DNA High Sensitivity Chip and qRT-PCR. High
quality libraries were sequenced on an Illumina HiSeq
2000. To achieve comprehensive coverage for each
sample, we generated ~25–30 million single end reads.
RNASEQ data analysis
The raw RNA sequencing data was processed to remove
any adaptor, PCR primers and low quality transcripts using
FASTQC and Fastx softwares. These provide a very com-
prehensive estimate of sample quality on the basis of read
quality, read length, GC content, uncalled bases, ratio of
bases called, sequence duplication, adaptor and PCR primer
contamination. Initially all Illumina TruSeq2 specific adap-
tors were removed. The bases from start and end of reads
that are below quality threshold (Phred Score <20)
were trimmed. The reads with average quality Phred qual-
ity score <20 were removed from further analysis. Post-
trimming, the reads with length less than 36 were removed
from analysis to avoid any non-specific mapping. The reads
with >10 % N bases calls were removed from analysis.
After preprocessing and filtering high quality, clean reads
were aligned against human genome using tophat2 and
bowtie2 packages (http://ccb.jhu.edu/software/tophat/
index.shtml) [25]. We used hg19 human genome assembly
as reference genome for alignment. Gene expression meas-
urement was performed from aligned reads by counting
the unique reads using htseq-count algorithm. The read
count based gene expression data was normalized on the
basis of library complexity and gene variation using the R
package EdgeR [26]. The normalized count data was
compared among groups using a negative binomial model
to identify differentially expressed genes. The differentially
expressed genes were identified on the basis of mul-
tiple-test corrected P value and fold change. Genes were
considered significantly differentially expressed if the
p-value was <5 % FDR and absolute fold change >2.
Unsupervised analysis
Unsupervised analysis was performed using Principal
Component Analysis (PCA), which projects multivariate
data objects onto a lower dimensional space while
retaining as much of the original variance as possible.
Gene ontology (GO) analysis
To identify over-represented GO categories in differen-
tially expressed genes, we used the Biological Processes
and Molecular Functions Enrichment Analysis available
from the Database for Annotation, Visualization and
Integrated Discovery (DAVID) [27]. DAVID is an online
implementation of the EASE software that produces a
list of over-represented categories using jackknife itera-
tive re-sampling of the two-tailed Fisher exact probabil-
ities [27]. A p-value gets assigned to each category on
the basis of enrichments. Smaller p-values reflect
increasing confidence in over-representation. The GO
categories with p-values <0.01 and at least 3 genes were
considered significant.
Pathway and interactive network analysis
Ingenuity Pathway Analysis (IPA 8.0, Qiagen) was used
to identify the pathways and interaction networks that
are significantly affected by significantly differentially
expressed genes. The knowledge base of this software
consists of functions, pathways and network models
derived by systematically exploring the peer reviewed
scientific literature. A detailed description of IPA ana-
lysis is available at the Ingenuity Systems’ web site
(www.ingenuity.com). It calculates a p-value for each
pathway according to the fit of users’ data to the IPA
database using one-tailed Fisher exact test. The pathways
with p-values <0.01 were considered significantly af-
fected. For each network, IPA calculates a score derived
from the p-value of one-tailed Fisher exact test [score =
−log (p-value)] and indicates the likelihood of focus
genes appearing together in the network due to random
chance. A score of 2 or higher has at least a 99 % probabil-
ity of not being generated by random chance alone. The
ability to rank the networks based on their relevance to
the queried data sets allows for prioritization of networks
with the strongest association with pre-to post-
intervention changes.
Regulatory module analysis
The regulatory module analysis was used to identify the
cascade of upstream transcriptional regulators that can
explain the observed gene expression changes to help
identify key regulators (master regulators) and under-
stand the underlying biological mechanism [28]. The
analysis helps in identifying first which transcription reg-
ulators are significantly affected by the treatment and
then determine whether they are activated or inhibited.
The activation or inhibition of transcriptional regulators
was assessed by determining the overlap among users
data with activation or inhibition signatures of regula-
tors. The significance of overlap was determined using
one tailed fisher Exact test.
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Quantitative real time PCR
Quantitative RT-PCR (qRT-PCR) was performed on each
of the three biological replicates for each of the treat-
ment conditions as described to validate changes in key
genes [29]. Briefly, cDNA was obtained from 100 ng of
total RNA using iScript reverse transcriptase from BioRad
(Hercules, California). Specific gene targeting primers
were obtained from Integrated DNA Technologies,
(Coralville, Iowa). All primers were used at a concentra-
tion varying between 600nM and 900nM. Gene sequences
are presented in Additional file 1: Table S1. PCR was
performed using Brilliant III Ultra-Fast SYBR® QPCR
Master Mix in conjunction with the Agilent Mx3005P
PCR machine (Agilent Technologies, Santa Clara, CA).
Beta-2-Microglobulin (B2M) was used as a house-keeping
gene. For quantitative analysis, target gene levels were
normalized to B2M levels as previously described, [30]
and target and housekeeper gene amplification reactions
were performed in duplicate for each of the cDNA sample
(three biological replicate for each treatment condition)
using 1 μl cDNA per reaction. For validation of differen-
tially expressed genes, chemokine chemokine (C-C motif)
ligand 8 (CCL-8), also known as monocyte chemo-
attractant protein 2 (MCP-2), Signal Transducer And
Activator Of Transcription (STAT)-4, IL-1α and IL-
1β, specific primers were used. All data are expressed
as the mean ± SEM and are analyzed using One-Way
ANOVA test. An unpaired t-test was performed and
p < 0.05 was considered statistically significant.
Supporting data
Additional information and data set(s) supporting the
results of this article are included within the article as an
Additional file 1.
Additional file
Additional file 1: Supplementary Tables. (XLS 138 kb)
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